HOLON, ISRAEL, Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data an ...

We expect investors to focus on Compugen Ltd.’s (CGEN) progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteCompugen’s top line currently comprises revenues recognized from its license agreement with Gilead Sciences (GILD) and AstraZeneca. The company reported $6.7 million in revenues in the last reported quarter, comprising an upfro ...

Compugen (CGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing e ...

HOLON, Israel, Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Monday, September 9, 2024, 7:00 AM ET for 30 days. About Compugen Compugen is a clinical ...

Investors might want to bet on Compugen (CGEN) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. Analysts' growing optimism on the earnings prospects of this drug developer is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...

Compugen Ltd. (NASDAQ:CGEN) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Ren ...

Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 75%. A quarter ago, it was expected that this drug developer would post a loss of $0.10 per share when it actually produced a loss of $0.08, delivering a surprise of 20%. Over the last four quarters, the company has surpassed co ...

FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential r ...

Core Insights - The FDA has granted clearance for Compugen's investigational new drug application for COM503, leading to a $30 million milestone payment from Gilead [1][2] - Compugen plans to initiate a Phase 1 trial for COM503 in advanced solid tumors in Q4 2024 [1][2] Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in computational target discovery [5] - The company has two proprietary product candidates in Phase 1 development: COM701 and COM902, alongside COM503 [5] COM503 Details - COM503 is a high affinity anti-IL-18 binding protein antibody, which is being developed as a monotherapy and in combination with Gilead's anti-PD-1 antibody, zimberelimab [3][4] - The Phase 1 trial will assess the safety and tolerability of COM503 in participants with advanced or metastatic solid tumors globally [3] Partnership with Gilead - In 2023, Compugen and Gilead entered a license agreement granting Gilead exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including COM503 [4] - Gilead provided an upfront payment of $60 million and will make additional milestone payments, with a total deal value of up to $848 million [4]

HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France. About Compugen Company contact: Yv ...